BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 19402094)

  • 21. TMPRSS2-ERG gene fusion is rare compared to PTEN deletions in stage T1a prostate cancer.
    Fisher KW; Zhang S; Wang M; Montironi R; Wang L; Baldrige LA; Wang JY; MacLennan GT; Williamson SR; Lopez-Beltran A; Cheng L
    Mol Carcinog; 2017 Mar; 56(3):814-820. PubMed ID: 27500376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers.
    Krohn A; Seidel A; Burkhardt L; Bachmann F; Mader M; Grupp K; Eichenauer T; Becker A; Adam M; Graefen M; Huland H; Kurtz S; Steurer S; Tsourlakis MC; Minner S; Michl U; Schlomm T; Sauter G; Simon R; Sirma H
    J Pathol; 2013 Sep; 231(1):130-41. PubMed ID: 23794398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor.
    Xin L; Teitell MA; Lawson DA; Kwon A; Mellinghoff IK; Witte ON
    Proc Natl Acad Sci U S A; 2006 May; 103(20):7789-94. PubMed ID: 16682621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Expression of androgen receptor protein in hormone refractory prostate cancer].
    Zhang Y; Chen W; Hu XK; Gui ZN
    Ai Zheng; 2003 Jan; 22(1):95-7. PubMed ID: 12561446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
    Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer.
    Reid AH; Attard G; Brewer D; Miranda S; Riisnaes R; Clark J; Hylands L; Merson S; Vergis R; Jameson C; Høyer S; Sørenson KD; Borre M; Jones C; de Bono JS; Cooper CS
    Mod Pathol; 2012 Jun; 25(6):902-10. PubMed ID: 22460813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development.
    Jiao J; Wang S; Qiao R; Vivanco I; Watson PA; Sawyers CL; Wu H
    Cancer Res; 2007 Jul; 67(13):6083-91. PubMed ID: 17616663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading.
    Picanço-Albuquerque CG; Morais CL; Carvalho FL; Peskoe SB; Hicks JL; Ludkovski O; Vidotto T; Fedor H; Humphreys E; Han M; Platz EA; De Marzo AM; Berman DM; Lotan TL; Squire JA
    Virchows Arch; 2016 May; 468(5):607-17. PubMed ID: 26861919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors.
    Qu X; Randhawa G; Friedman C; Kurland BF; Glaskova L; Coleman I; Mostaghel E; Higano CS; Porter C; Vessella R; Nelson PS; Fang M
    PLoS One; 2013; 8(9):e74671. PubMed ID: 24098661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer.
    Bismar TA; Yoshimoto M; Duan Q; Liu S; Sircar K; Squire JA
    Histopathology; 2012 Mar; 60(4):645-52. PubMed ID: 22260502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients.
    McCall P; Gemmell LK; Mukherjee R; Bartlett JM; Edwards J
    Br J Cancer; 2008 Mar; 98(6):1094-101. PubMed ID: 18349820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of a small region around the PTEN locus is a major chromosome 10 alteration in prostate cancer xenografts and cell lines.
    Hermans KG; van Alewijk DC; Veltman JA; van Weerden W; van Kessel AG; Trapman J
    Genes Chromosomes Cancer; 2004 Mar; 39(3):171-84. PubMed ID: 14732919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GATA2 negatively regulates PTEN by preventing nuclear translocation of androgen receptor and by androgen-independent suppression of PTEN transcription in breast cancer.
    Wang Y; He X; Ngeow J; Eng C
    Hum Mol Genet; 2012 Feb; 21(3):569-76. PubMed ID: 22021428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells.
    Lin HK; Hu YC; Lee DK; Chang C
    Mol Endocrinol; 2004 Oct; 18(10):2409-23. PubMed ID: 15205473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer.
    Mulholland DJ; Dedhar S; Wu H; Nelson CC
    Oncogene; 2006 Jan; 25(3):329-37. PubMed ID: 16421604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer.
    Gao H; Ouyang X; Banach-Petrosky WA; Gerald WL; Shen MM; Abate-Shen C
    Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14477-82. PubMed ID: 16973750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
    Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ
    BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Id4 deficiency attenuates prostate development and promotes PIN-like lesions by regulating androgen receptor activity and expression of NKX3.1 and PTEN.
    Sharma P; Knowell AE; Chinaranagari S; Komaragiri S; Nagappan P; Patel D; Havrda MC; Chaudhary J
    Mol Cancer; 2013 Jun; 12():67. PubMed ID: 23786676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathological effects of prostate cancer correlate with neuroendocrine differentiation and PTEN expression after bicalutamide monotherapy.
    Ham WS; Cho NH; Kim WT; Ju HJ; Lee JS; Choi YD
    J Urol; 2009 Oct; 182(4):1378-84. PubMed ID: 19683286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of lncRNAs in prostate cancer development and progression.
    Weiss M; Plass C; Gerhauser C
    Biol Chem; 2014 Nov; 395(11):1275-90. PubMed ID: 25153594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.